Our Mission

Our Aim is the concrete treatment of Mitochondrial Diseases.

The 7 SEAS PROJECT is to develop treatment for these diseases via study and research into Mitochondrial and related diseases.

This project is managed by “KOINOBORI Associate Inc.” We are a unique pro-bono team and nonprofit corporation. The members include doctors, venture capitalists, researchers, biotech company directors, patients and their families.
The 7 SEAS PROJECT representative is the father of mitochondria patient. We would like to provide treatment to Mitochondria patients as soon as possible.




Business Model

Drug development social project

7 SEAS PROJECT is a non-profit drug development social project.
We will return profits from the development of therapeutic methods for treating mitochondrial and related diseases to patients and their families.
To achieve our project, we use donations and research funding in collaboration with universities and laboratories.

In order to continue this business model, we actively carry out the development drugs and therapies for mitochondrial and related diseases including Parkinson’s disease, Alzheimer’s disease, Myocardial infarction, Neurodegenerative diseases, Diabetes (Type2-Diabetes). We are conducting marker discovery and developing treatments for these diseases.




Corporate Information


Representative: Tomoaki Shinohara
Office: 2-1-9, Higashikaigankita, Chigasaki, Kanagawa, 253-0053, Japan
(KOINOBORI Associate Inc Kanagawa Branch)
Established in October, 2016

Contact us




Management Team


Tomoaki Shinohara : 7 SEAS PROJECT Representative, KOINOBORI Director

2017- KOINOBORI Director
7 SEAS PROJECT Representative
Kanagawa prefecture public school administrative staff
Sophia University foreign language department


Masashi Suganuma, MD, PhD :7SEAS PROJECT Co-Representative, KOINOBORI President

2013- KOINOBORI President
The medical institution Suganuma Clinic, President
CanBas Co., Ltd, founder and Representative Director
Fujita Health University, surgical hospital instructor
Nagoya City University School of Medicine, Faculty of Molecular Medicine Research Instructor
Fujita Health University School of Medicine, Postgraduate degree Doctor of Medicine


Taro Inaba : KOINOBORI director

2013- KOINOBORI director
REMIGES Ventures, Founder and Managing Partner
Mitsui & Co., Mitsui & Co. Global Investment
European University, MBA
Kyoto University, Bachelor of Engineering


Kinji Fuchikami : KOINOBORI director

2013- KOINOBORI director
Mitsui & Co. Global Investment, Venture Partner
In-Silico Sciences, Inc., Representative Director
Bayer Yakuhin Research Center Kyoto
Osaka University Graduate School of Medicine





Apr. 2009 We founded “KOINOBORI″, a drug development NPO for rare diseases.
Aug. 2009 Mitochondria disease was diagnosed in a member of KOINOBORI’s president’s family. Consequently, the president and the team at KOINOBORI decided to devote their efforts to the challenge of mitochondrial disease.
Oct. 2012 KOINOBORI supported EPI-743 for compassionate use at the Kanagawa Children’s Medical Center.
Jan.2013 “KOINOBORI″ became a nonprofit general incorporated association.
May. 2013 KOINOBORI supported the clinical study of EPI-743 at the National Center of Neurology and Psychiatry (Tokyo).
Jun. 2013 Partnership with The United Mitochondrial Disease Foundation (UMDF) in the USA.
Jul. 2014 Patient and family “ACTION” meeting in Tokyo.
Dec. 2014 Patient and family “ACTION” meeting in Fukuoka.
Mar. 2015 Patient and family “ACTION” meeting in Osaka.
Aug. 2015 Invited Stealth Bio Therapeutics Co. to the neuro-ophthalmology society’s annual conference.
Nov. 2015 The 1st Ethics Committee Meeting of KOINOBORI.
Dec. 2015 Start of observational research for Mitochondria disease.
Apr. 2016 Plan to establish the “7 SEAS PROJECT”.
Jul. 2017 “7 SEAS PROJECT”’s kick-off Meeting in Tokyo.